SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Dec 4, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Dec. 4, 2018 · CIK: 0001430306 · Accession: 0001615774-18-013771
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227228
Letter
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
December 4, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention Irene Paik
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-1 (File No. 333-227228)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 8:30 a.m., Eastern Standard Time, on December 6, 2018, or as soon as practicable thereafter.
Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
December 4, 2018
Page 2
Very truly yours,
TONIX
PHARMACEUTICALS HOLDINGS CORP.
Show Raw Text
CORRESP
1
filename1.htm
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
December 4, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention Irene Paik
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-1 (File No. 333-227228)
Ladies and Gentlemen:
In accordance with
Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective
by the Securities and Exchange Commission (the “Commission”) at 8:30 a.m., Eastern Standard Time, on December
6, 2018, or as soon as practicable thereafter.
Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any
questions.
[Signature page follows.]
U.S.
Securities and Exchange Commission
December
4, 2018
Page 2
Very truly yours,
TONIX
PHARMACEUTICALS HOLDINGS CORP.
By:
/s/ Bradley Saenger
Name: Bradley Saenger
Title: Chief Financial Officer
-2-